Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions
Intrapartum Fetal DistressNeonatal AsphyxiaIntrapartum AsphyxiaInstrumental Delivery; Affecting Fetus
Interventions
DRUG

Sildenafil 50 mg Oral Tablet

Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor

DRUG

Placebo Oral Tablet

Placebo tablet given orally every eight hours up to three times while mother is in labor

Trial Locations (4)

101001

Lagos Island Maternity Hospital, Lagos

101241

Mother and Child Hospital, Surulere

102215

University Teaching Hospital, University of Lagos, Lagos

210271

Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso

Sponsors
All Listed Sponsors
collaborator

University of Lagos, Nigeria

OTHER

collaborator

Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso

OTHER

collaborator

Lagos State University

OTHER

collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Mater Medical Research Institute

OTHER

collaborator

The University of Queensland

OTHER

lead

University of Alabama at Birmingham

OTHER